Theravance Biopharma, Inc. Restructuring and Related Cost, Expected Number of Positions Eliminated
Theravance Biopharma, Inc. (TBPH) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 51 employee for the 1-month period ending 2019-01-31, per its 10-Q filed 2019-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2021-02-26
- 2019-01-31: Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month 51.00 employee.
employee
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month |
|---|---|
| 2019-01-31 | 51.00 employee 10-Q · filed 2019-05-10 |
individual
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month |
|---|---|
| 2019-01-31 | 51.00 individual 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |